Adjuvant endocrine therapies used in the treatment of breast cancer may cause multiple adverse drug events (ADEs), which can reduce patients’ quality of life and hinder treatment adherence if not p...
<p><strong>Tác giả:</strong> Nguyễn Thị Liên Hương, Tran Thi Thu Trang, Nguyen Thi Yen, Doan Thu Quyen, Nguyen Thi Hong Hanh, Nguyen Tu Son, Bui Van Giang</p>
<p>Adjuvant endocrine therapies used in the treatment of breast cancer may cause multiple adverse drug events (ADEs), which can reduce patients’ quality of life and hinder treatment adherence if not properly managed. A cross-sectional study was conducted at Provincial Oncology Hospital among patients who had been prescribed tamoxifen or aromatase inhibitors (AIs) for at least 3 months. ADEs occurring within the previous 4 weeks were recorded and their severity assessed using a 4-point Likert sca...</p>
<p>📄 DOI: <a href="https://doi.org/https://doi.org/10.25073/2588-1132/vnumps.4982" target="_blank" rel="noopener">https://doi.org/10.25073/2588-1132/vnumps.4982</a></p>
<p>📖 <a href="https://doi.org/https://doi.org/10.25073/2588-1132/vnumps.4982" target="_blank" rel="noopener">Xem bài báo đầy đủ</a></p>
Bài viết được biên soạn lại bởi LIFVietnam. Nguồn tham khảo: OpenAlex